Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/6/2018
SIETES contiene 92380 citas

 
 
 1 a 20 de 608 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med 2018:5 de junio. [Ref.ID 102647]
2. Cita con resumen
Grosser T, Ricciotti E, Fitzgerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 2017;38:733-48. [Ref.ID 101990]
3. Cita con resumen
Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiology 2016:9 de noviembre. [Ref.ID 100967]
4. Cita con resumen
Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, Stanczyk FZ, Selzer RH, Azen SP, ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221-31. [Ref.ID 100167]
5.Enlace a cita original Cita con resumen
Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Review of Clinical Pharmacology 2015;8:189-99. [Ref.ID 99700]
6. Cita con resumen
Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]
7.Enlace a cita original
Fang J, George MG, Hong Y, Loustalot F. Use of aspirin for prevention of recurrent atherosclerotic cardiovascular disease among adults — 20 States and the district of Columbia, 2013. Morbidity and Mortality Weekly Report 2015;64:733-7. [Ref.ID 99265]
8. Cita con resumen
Ross JS, Frazee SG, Garavaglia SB, Levin R, Novshadian H, Jackevicius CA, Stettin G, Krumholz HM. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. JAMA Intern Med 2014;174:1486-93. [Ref.ID 97900]
9.Tiene citas relacionadas Cita con resumen
Bittl JA. Treatment of atherosclerotic renovascular disease. N Engl J Med 2014;370:78-9. [Ref.ID 97025]
10.Tiene citas relacionadas Cita con resumen
Cooper CJ, Murphy TP, Cutlip DE, Jamerson k, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB, Dworkin LD, for the CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370:13-22. [Ref.ID 97024]
11.Tiene citas relacionadas
Doroshow JH. Overcoming resistance to targeted anticancer drugs. N Engl J Med 2013;369:1852-3. [Ref.ID 96519]
12.Tiene citas relacionadas
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Godlman JM, Shah NP, Kantarjian H, PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96. [Ref.ID 96515]
13.Tiene citas relacionadas Cita con resumen
Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cadiovascular surveillance. N Engl J Med 2013;369:1779-81. [Ref.ID 96514]
15. Cita con resumen
Anónimo. Nilotinib: effets indésirables cardiovasculaires. Prescrire 2013;33:667. [Ref.ID 96187]
16.Tiene citas relacionadas Cita con resumen
Nicholls SJ, Bakris GL, Kastelein JJP, Menon V, Williams B, Ambrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 2013;310:1135-44. [Ref.ID 96112]
17.Tiene citas relacionadas
Tardif JC, Grégoire J. Renin-angiotensin system inhibition and secondary cardiovascular prevention. JAMA 2013;310:1130-1. [Ref.ID 96110]
18. Cita con resumen
Stefanini GG, Homes Jr DR. Drug therapy: drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65. [Ref.ID 94789]
19.Tiene citas relacionadas Cita con resumen
McGreevy C, Williams D. New insights about vitamin D and cardiovascular disease. A narrative review. Ann Intern Med 2011;155:820-6. [Ref.ID 91694]
20. Cita con resumen
Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-87. [Ref.ID 91659]
Seleccionar todas
 
 1 a 20 de 608 siguiente >>